Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Let’s take a closer look at a few biotech stocks poised to benefit from this resurgence. Medicus Pharma Ltd. (NASDAQ: MDCX) is an emerging biotech and life sciences company with a global footprint ...

The TSLP inhibitors market is witnessing steady growth, driven by the increasing prevalence of asthma, atopic dermatitis, and other allergic inflammatory diseases. Rising adoption of targeted ...

Although metformin has been the go-to medication to manage type 2 diabetes for more than 60 years, researchers still do not have a complete picture of how it works.

Cancer represents the most extensively studied disease category involving transcription factor dysregulation, with multiple TFs driving distinct oncogenic mechanisms. Hypoxia-inducible factors (HIFs), ...